DRTX Share Price

Open 23.82 Change Price %
High 24.17 1 Day 0.41 1.73
Low 23.80 1 Week 0.00 0.00
Close 24.16 1 Month 0.00 0.00
Volume 1079764 1 Year 0.00 0.00
52 Week High 2.37
52 Week Low 0.99
DRTX Important Levels
Resistance 2 24.50
Resistance 1 24.36
Pivot 24.04
Support 1 23.96
Support 2 23.82
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
MU 20.45 7.29%
MU 20.45 7.29%
MU 20.45 7.29%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ANTH 2.03 38.10%
EMKR 8.45 31.01%
MBLX 0.32 28.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 8.00 23.08%
ATEA 1.95 21.88%
ATEA 1.95 21.88%
More..
NASDAQ USA Top Losers Stocks
DSTI 0.00 -100.00%
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Durata Therapeutics, Inc. (NASDAQ: DRTX)

DRTX Technical Analysis 5
As on 17th Nov 2014 DRTX Share Price closed @ 24.16 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.44 & Strong Buy for SHORT-TERM with Stoploss of 19.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
DRTX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DRTX Other Details
Segment EQ
Market Capital 140759232.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.duratatherapeutics.com
DRTX Address
DRTX
200 Sourth Wacker Drive
Suite 2550
Chicago, IL 60606
United States
Phone: 312-219-7000
DRTX Latest News
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer   PR Newswire (press release)   - 17th Nov 14
Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)   GlobeNewswire (press release)   - 10th Oct 14
Top Gainers: NXT-ID Inc. (NASDAQ:NXTD), Durata Therapeutics Inc. (NASDAQ:DRTX ...   US Trade Media (registration)   - 06th Oct 14
Actavis agrees to acquire Durata Therapeutics   MarketWatch   - 06th Oct 14
Stock Watch: Wave Systems Corp. (NASDAQ:WAVX); Durata Therapeutics Inc (NASDAQ ...   US Trade Media (registration)   - 06th Oct 14
FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its ...   GlobeNewswire (press release)   - 03rd Oct 14
Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With ...   GlobeNewswire (press release)   - 30th Jul 14
Durata Therapeutics Announces the US Launch of DALVANCE(TM)   GlobeNewswire (press release)   - 18th Jul 14
Why Durata Therapeutics Inc. Shares Tumbled   Motley Fool   - 27th May 14
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?   Motley Fool   - 05th Apr 14
Interactive Technical Analysis Chart Durata Therapeutics, Inc. ( DRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Durata Therapeutics, Inc.
DRTX Business Profile
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.